A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 and 2017 black patients were 24% less likely than white patients to have a prostate MRI after receiving an elevated (prostate-specific antigen) PSA score

Courtesy Getty Images


November 16, 2021 — A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 and 2017 black patients were 24% less likely than white patients to have a prostate MRI after receiving an elevated (prostate-specific antigen) PSA score. For patients with an elevated PSA, use of prostate MRI prior to prostate biopsy has increased substantially in recent years as MRI can improve identification of clinically significant prostate cancer and obviate the need for biopsy, thus decreasing overdiagnosis of these cases. This JAMA Network Open study was based on 794,809 men, age 40 or older, with a PSA test using claims data from the Optum Clinformatics Data Mart Database. Of these men, 51,500 had an PSA score >4ng/mL. The study found that patients with Medicare compared to commercial insurance were less likely to have a prostate MRI as were patients with HMO insurance plans compared to other plan types.

“Compared to White patients, Black, Hispanic, and Asian patients were significantly less likely to undergo prostate MRI within 180 days after an elevated PSA result,” said first author Nino Abashidze, Ph.D., postdoctoral researcher at the University of Wyoming. Specifically, black patients were 24% and 35% less likely than white patients to have a prostate MRI for those with PSA >4 and >10, respectively. Hispanic patients with PSA >10 were 23% less likely than white patients to have a prostate MRI and Asian patients with PSA>4 were 24% less likely than white patients. “These large racial and ethnic disparities highlight the need for additional research to better understand and mitigate clinical decision-making biases and other potential sources of these disparities, such as physician characteristics or biases in the health care system.”

“Interestingly, the racial and ethnic disparities observed were insignificant among patients over 75 years of age – a population for which the U.S. Preventive Services Task Force recommends against screening for prostate cancer,” said senior author Danny Hughes, Ph.D., director of Georgia Tech’s Health Economics & Analytics Lab (HEAL) and NHPI Senior Research Fellow. Significant differences between whites and black, Hispanic, and Asian patients were found at all other age groups (40-54, 55-64, 65-74) but not for those 75 or more. “This indicates the important role that clearly defined guidelines can play in addressing racial and ethnic disparities in care. For the age groups for which prostate cancer screening is recommended, clearer guidelines are still needed for the optimal use of prostate MRI.”

For more information: www.neimanhpi.org

Related Prostate Cancer Information:

Why Black Men's Prostate Cancer May be More Responsive to Immunotherapy

Mount Sinai Receives $3.8 Million Gift to Launch Mobile MRI Unit to Support Prostate Health in the Black Community

Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer

Related Content

News | Prostate Cancer

July 1, 2022 — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care ...

Time July 01, 2022
arrow
News | Proton Therapy

July 1, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology ...

Time July 01, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

June 30, 2022 — When a patient with head and neck cancer has surgery to remove it, they often need reconstructive ...

Time June 30, 2022
arrow
News | Proton Therapy

June 29, 2022 — ProtOnART builds upon the partners’ long-standing research efforts and shared ambition that an online ...

Time June 29, 2022
arrow
News | Lung Imaging

June 29, 2022 — Building on Penn Medicine’s years of research and use of imaging technology that illuminates tumor ...

Time June 29, 2022
arrow
News | Proton Therapy

June 27, 2022 — Varian, a Siemens Healthineers company, announced that the U.S. Food and Drug Administration (FDA) ...

Time June 28, 2022
arrow
News | Radiation Oncology

June 27, 2022 — Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they ...

Time June 28, 2022
arrow
News | Radiation Therapy

June 24, 2022 — Recently, a collaborated research team led by Prof. LI Hai and Hongzhi Wang from Hefei Institutes of ...

Time June 24, 2022
arrow
News | Radiation Therapy

June 23, 2022 — RaySearch Laboratories AB announced the release of the latest version of RayCare*, the next generation ...

Time June 23, 2022
arrow
News | Radiation Therapy

June 17, 2022 — Accuray Incorporated and Limbus AI Inc. announced they are partnering to augment Accuray adaptive ...

Time June 17, 2022
arrow
Subscribe Now